Logo

Princeton Licenses Oncology Genes to Genome Therapeutics

Dec 18, 1998
Premium

WALTHAM, Mass.--Genome Therapeutics here announced that it acquired an exclusive license to proprietary genes regulated by the T53 tumor suppressor gene from Prince ton University. The agreement will enable Genome Therapeutics to develop proprietary targets within the p53 signal pathway that could lead to the identification of potential gene therapies and the development of new cancer treatments. Under terms of the agreement, Princeton will receive an undisclosed license fee and share in any product royalties created through future alliances.

Filed under

Informatics
Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.